CASPIAN研究更新结果:度伐利尤单抗联合铂类-依托泊苷一线治疗广泛期小细胞肺癌
CASPIAN是一项开放标签、随机对照3期试验,纳入805例初治广泛期小细胞肺癌患者,比较度伐利尤单抗联合铂类-依托泊苷(±替西木单抗)与单纯化疗。
要点
- 度伐利尤单抗联合化疗组3级及以上中性粒细胞减少发生率为24%,严重不良事件发生率为32%。
核心结论
- 一线度伐利尤单抗联合铂类-依托泊苷较单纯化疗持续改善总生存,支持其作为ES-SCLC新标准治疗。
- 在度伐利尤单抗联合化疗基础上加用替西木单抗未显著改善总生存。
研究设计与样本
- CASPIAN为正在进行的开放标签、申办方盲法、随机对照3期试验,在全球23个国家209个癌症治疗中心开展。
- 纳入805例初治、组织学或细胞学证实的广泛期小细胞肺癌患者,WHO体能状态0或1,按1:1:1随机分组。
- 三组分别为度伐利尤单抗+替西木单抗+铂类-依托泊苷组(268例)、度伐利尤单抗+铂类-依托泊苷组(268例)和单纯铂类-依托泊苷组(269例)。
- 主要终点为意向治疗人群中度伐利尤单抗+铂类-依托泊苷 vs 单纯化疗、以及度伐利尤单抗+替西木单抗+铂类-依托泊苷 vs 单纯化疗的总生存。
主要发现
- 任何原因3级及以上不良事件最常见为中性粒细胞减少(三组分别为32%、24%、33%)和贫血(13%、9%、18%)。
- 任何原因严重不良事件发生率分别为45%、32%、36%;治疗相关死亡分别为5%、2%、1%。
关键数值与推荐
- 度伐利尤单抗+替西木单抗+化疗组、度伐利尤单抗+化疗组、化疗组3级及以上中性粒细胞减少发生率分别为32%、24%、33%。
- 三组任何原因严重不良事件发生率分别为45%、32%、36%;治疗相关死亡率分别为5%、2%、1%。
临床怎么用
- 对于初治广泛期小细胞肺癌且体能状态0-1的患者,可考虑度伐利尤单抗联合铂类-依托泊苷作为一线治疗。
- 不推荐在度伐利尤单抗联合铂类-依托泊苷基础上常规加用替西木单抗,因未显著改善总生存。
- 治疗期间需监测中性粒细胞减少和贫血等不良事件,以及免疫相关不良事件。
局限性
- 本研究为开放标签设计,申办方盲法,可能存在偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone. METHODS: CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment-naive, histologically or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-response system to receive intravenous durvalumab plus tremelimumab plus platinum-etoposide, durvalumab plus platinum-etoposide, or platinum-etoposide alone. In all groups, patients received etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m2 on day 1 of each cycle. Patients in the platinum-etoposide group received up to six cycles of platinum-etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum-etoposide versus platinum-etoposide and for durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872. FINDINGS: Between March 27, 2017, and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum-etoposide, 268 to durvalumab plus platinum-etoposide, and 269 to platinum-etoposide). As of Jan 27, 2020, the median follow-up was 25·1 months (IQR 22·3-27·9). Durvalumab plus tremelimumab plus platinum-etoposide was not associated with a significant improvement in overall survival versus platinum-etoposide (hazard ratio [HR] 0·82 [95% CI 0·68-1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6-12·0) versus 10·5 months (9·3-11·2). Durvalumab plus platinum-etoposide showed sustained improvement in overall survival versus platinum-etoposide (HR 0·75 [95% CI 0·62-0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3-14·7) versus 10·5 months (9·3-11·2). The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum-etoposide group, and 88 [33%] of 266 patients in the platinum-etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). Any-cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 85 (32%) in the durvalumab plus platinum-etoposide group, and 97 (36%) in the platinum-etoposide group. Treatment-related deaths occurred in 12 (5%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum-etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in the platinum-etoposide group (pancytopenia and thrombocytopenia [n=1 each]). INTERPRETATION: First-line durvalumab plus platinum-etoposide showed sustained overall survival improvement versus platinum-etoposide but the addition of tremelimumab to durvalumab plus platinum-etoposide did not significantly improve outcomes versus platinum-etoposide. These results support the use of durvalumab plus platinum-etoposide as a new standard of care for the first-line treatment of ES-SCLC. FUNDING: AstraZeneca.
引用
- Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2020. PMID: 33285097. doi:10.1016/S1470-2045(20)30539-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。